Xinyi Jiang

Dr. Xinyi Jiang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
PHPilar Hernandez-Con
Pilar Hernandez-Con
DWDebbie Wilson
Debbie Wilson
HTHuilin Tang
Huilin Tang
IUIkenna Unigwe
Ikenna Unigwe
MRMunaza Riaz
Munaza Riaz
HPHaesuk Park
Haesuk Park

1 April 2018 in Clinical Therapeutics
Verified
Journal Article
Closed access
XJXinyi Jiang
Xinyi Jiang
HXHong Xiao
Hong Xiao
RSRichard Segal
Richard Segal
WMWilliam Cary Mobley
William Cary Mobley
HPHaesuk Park
Haesuk Park

16 May 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
SVScott Martin Vouri
Scott Martin Vouri
XJXinyi Jiang
Xinyi Jiang
EMEarl J. Morris
Earl J. Morris
BBBabette A. Brumback
Babette A. Brumback
AWAlmut G. Winterstein
Almut G. Winterstein

25 January 2024 in Public Health Reports®
Verified
Journal Article
Closed access
JDJill A. Dever
Jill A. Dever
MHMarci F. Hertz
Marci F. Hertz
LDLaura J. Dunlap
Laura J. Dunlap
JRJohn S. Richardson
John S. Richardson
SWSara Beth Wolicki
Sara Beth Wolicki
GGGery P. Guy
Gery P. Guy
Objective: Opioid use disorder (OUD) affects approximately 5.6 million people in the United States annually, yet rates of the use of effective medication for OUD (MOUD) treatment are low. We conducted an observational cohort study from August 2017 through May 2021, the MOUD Study, to better understand treatment engagement and factors that may influence treatment experiences and outcomes. In this article, we describe the study design, data collected, and treatment outcomes. Methods: We recruited adult patients receiving OUD treatment at US outpatient facilities for the MOUD Study. We collected patient-level data at 5 time points (baseline to 18 months) via self-administered questionnaires and health record data. We collected facility-level data via questionnaires administered to facility directors at 2 time points. Across 16 states, 62 OUD treatment facilities participated, and 1974 patients enrolled in the study. We summarized descriptive data on the characteristics of patients and OUD treatment facilities and selected treatment outcomes. Results: Approximately half of the 62 facilities were private, nonprofit organizations; 62% focused primarily on substance use treatment; and 20% also offered mental health services. Most participants were receiving methadone (61%) or buprenorphine (32%) and were predominately non-Hispanic White (68%), aged 25-44 years (62%), and female (54%). Compared with patient-reported estimates at baseline, 18-month estimates suggested that rates of abstinence increased (55% to 77%), and rates of opioid-related overdoses (7% to 2%), emergency department visits (9% to 4%), and arrests (15% to 7%) decreased. Conclusions: Our results demonstrated the benefits of treatment retention not only on abstinence from opioid use but also on other quality-of-life metrics, with data collected during an extended period. The MOUD Study produced rich, multilevel data that can lay the foundation for an evidence base to inform OUD treatment and support improvement of care and patient outcomes.

17 November 2020 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
HPHaesuk Park
Haesuk Park
HSHyun Jin Song
Hyun Jin Song
XJXinyi Jiang
Xinyi Jiang
LHLinda Henry
Linda Henry
RCRobert L. Cook
Robert L. Cook
DNDavid R. Nelson
David R. Nelson
Medicaid prior authorization (PA) policies for treatment of hepatitis C virus (HCV) with direct-acting antiviral (DAA) therapy are changing. We aimed to evaluate effects of changes in PA requirements on treatment uptake and to determine the factors associated with DAA treatment among Florida Medicaid beneficiaries with HCV. This is a retrospective cohort analysis of Florida’s Medicaid administrative claims and electronic medical records (2013-2018). A total of 14,063 newly diagnosed patients with HCV were grouped based on human immunodeficiency virus (HIV) co-infection and/or a substance use disorder (SUD) (7,735 HCV mono-infected with a SUD, 5,180 HCV mono-infected without a SUD, 564 HCV/HIV co-infected with a SUD, and 584 HCV/HIV co-infected without a SUD). Although the treatment rate increased three-fold after June 1, 2016, when a fibrosis-stage restriction was eliminated, only 8% received DAAs. Compared to HCV mono-infected without a SUD, HCV mono-infected with a SUD and HCV/HIV co-infected with a SUD were 47% (adjusted hazard ratio, 0.53; 95% confidence interval, 0.47-0.60) and 59% (adjusted hazard ratio, 0.41; 95% confidence interval, 0.28-0.61) less likely to initiate DAAs. Those with HCV/HIV/SUD did not experience a DAA initiation increase after a fibrosis-stage restriction was eliminated. Compared with Whites, Blacks were less likely to receive DAAs but were more likely to complete treatment. Use of medication-assisted therapy was low, despite those on medication-assisted therapy being 60% more likely to initiate DAA therapy and no more likely to discontinue therapy. Conclusion: Despite changes in Florida’s Medicaid PA requirements for DAA treatment, only 8% received treatment. Disparities in treatment access were found among patients with HIV and a SUD, and who were Black. In our retrospective cohort study analysis using Florida Medicaid claims data (2013-2018), we examined the effects of prior authorization policy on access to direct-acting antiviral (DAA) treatment and identified factors associated with disparities among Florida Medicaid patients with hepatitis C virus (HCV). Our work shows that the number of Florida Medicaid patients treated for HCV has increased, but treatment rates are still very low (8%); compared to HCV mono-infected patients without substance use disorders (SUD), HCV mono-infected patients with SUD and HCV/HIV patients co-infected with SUD were 47% and 59% less likely to initiate DAAs, but no difference was observed in HCV/HIV patients co-infected without SUD. Disparities in access to treatment continue among patients with SUD, blacks, and pregnant women among Medicaid patients with HCV.

4 July 2024 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
XJXinyi Jiang
Xinyi Jiang
SCSarah Connolly
Sarah Connolly
ASAndrea E. Strahan
Andrea E. Strahan
LBLiz Rivera Blanco
Liz Rivera Blanco
CMChristina A. Mikosz
Christina A. Mikosz
DDDeborah Dowell
Deborah Dowell
This report describes reports of xylazine use among adults evaluated for substance use treatment.